

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong under the Companies Ordinance)*

**(Stock code: 1093)**

### **CHANGES OF EXECUTIVE DIRECTOR**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries (the “**Group**”)) hereby announces that (i) Mr. FENG Zhenying (“**Mr. FENG**”) resigned as an executive director of the Company with effect from 7 September 2015 due to retirement; (ii) Mr. LU Hua (“**Mr. LU**”) was appointed as an executive director of the Company with effect from 7 September 2015.

#### **Resignation of executive director**

Mr. FENG has confirmed that he has no disagreement with the Board and there are no other matters that need to be brought to the attention of the shareholders of the Company in relation to his resignation as an executive director of the Company.

The Board would like to take this opportunity to express its gratitude to Mr. FENG for his valuable contribution to the Company in the past years.

#### **Appointment of executive director**

Mr. LU, aged 43, joined the Group in 1996, is currently a senior vice president of the Group responsible for managing the production and operation of the bulk drug business. Mr. LU holds a bachelor’s degree in science (chemistry) from Hebei Normal University, a master’s degree in engineering (pharmaceutical manufacturing) from Beijing University of Chemical Technology, an EMBA degree from Tsinghua University and a doctorate in engineering (pharmaceutical manufacturing) from Tianjin University. Mr. LU has extensive experience in pharmaceutical engineering, production management and technical research. Mr. LU has not held any directorship in any public listed companies in the last three years. Save as disclosed above, Mr. LU has not held any other positions with the Group.

Mr. LU has entered into a service contract with the Company for a period of three years commencing from 7 September 2015 and his appointment is subject to retirement and re-election at the annual general meeting in accordance with the articles of association of the Company. Mr. LU is entitled to receive a monthly salary of RMB52,500 and an annual director’s fee of HK\$60,000. He is also eligible to receive performance related discretionary bonus to be determined by the Board. His emoluments were determined having giving consideration to the prevailing market practice, the Company’s remuneration policy and his level of responsibility.

As at the date of this announcement, Mr. LU has personal interests in share options granted under the Company's share option scheme to subscribe for 3,000,000 shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance. Mr. LU does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company. Save as disclosed above, Mr. LU confirmed that there is no other information required to be disclosed under Rule 13.51(2) of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited and there is no other matter relating to his appointment which needs to be brought to the attention of the shareholders of the Company.

By order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dongchen**  
*Chairman*

Hong Kong, 7 September 2015

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. CHAK Kin Man, Mr. PAN Weidong, Mr. WANG Shunlong, Mr. WANG Huaiyu, Mr. LU Jianmin, Mr. WANG Zhenguo, Mr. WANG Jinxu and Mr. Lu Hua as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Mr. LO Yuk Lam, Mr. YU Jinming and Mr. CHEN Shilin as independent non-executive directors.*